{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T15:28:30Z","timestamp":1795188510843,"version":"4.10.3"},"reference-count":17,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:sec id=\"ab-ebr250010-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are considered safe, effective medications for type 2 diabetes (T2D) and weight loss, used by millions worldwide. While their cardiometabolic benefits are well established, emerging observations suggest a potential association between GLP-1RA use and new-onset nonarteritic anterior ischemic optic neuropathy (NAION).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ebr250010-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To emulate a target trial evaluating the risk of NAION associated with initiation of semaglutide (GLP-1RA), compared with a sodium-glucose cotransporter-2 inhibitor (SGLT2i) as second-line therapy for T2D in a nationwide cohort of US veterans.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ebr250010-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This study was conducted nationwide using data from the Veterans Health Administration health care system between March 1, 2018, and March 1, 2025. This active-comparator, new-user, target trial emulation used cause-specific hazard ratios (HRs) that were estimated using overlap weighting to account for confounding. Participants included US veterans with T2D, current metformin use, and no prior GLP-1RA or SGLT2i use. Data analysis was conducted from July 2025 through September 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ebr250010-7\">\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>Initiation of semaglutide or any SGLT2i.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ebr250010-8\">\n                    <jats:title>Main Outcome and Measure<\/jats:title>\n                    <jats:p>\n                      Incident NAION, identified using\n                      <jats:italic toggle=\"yes\">International Statistical Classification of Diseases and Related Health Problems, Tenth Revision<\/jats:italic>\n                      and Systematized Nomenclature of Medicine codes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ebr250010-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 102\u202f361 US veterans met inclusion criteria, including 11\u202f478 initiators of semaglutide and 90\u202f883 initiators of an SGLT2i. Baseline characteristics were well balanced between treatment groups after overlap weighting (mean [SD] age, 60.1 [11.7] years; body mass index, 37.8 [6.7]; hemoglobin A\n                      <jats:sub>1c<\/jats:sub>\n                      , 7.0% [1.4]; 85.5% male and 14.5% female; 20.7% Black, 8.1% Hispanic, and 61.9% non-Hispanic White). Over a maximum follow-up of 7.5 years, 173 total incident NAION events occurred. The incidence rate of NAION was 123 per 100\u202f000 person-years among semaglutide initiators and 67 per 100\u202f000 person-years among SGLT2i. In 2.1 years of median follow-up, semaglutide initiators had a 2.33-fold higher risk than SGLT2i initiators (hazard ratio, 2.33; 95% CI, 1.54-3.54;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). The overlap weighted incidence rate of NAION was 0.29% for semaglutide initiators and 0.13% for SGLT2i initiators, with a corresponding average treatment effect of 0.16 percentage points.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ebr250010-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this nationwide cohort of US veterans with T2D, semaglutide initiators had a 2-fold NAION risk than SGLT2i initiators, while the absolute risk was low. Clinicians and patients should be counseled on the rare but evident increased risk of NAION after semaglutide initiation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2025.6262","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:30:53Z","timestamp":1770913853000},"page":"259","source":"Crossref","is-referenced-by-count":21,"title":["New-Onset Nonarteritic Anterior Ischemic Optic Neuropathy and Initiators of Semaglutide in US Veterans With Type 2 Diabetes"],"prefix":"10.1001","volume":"144","author":[{"given":"Kent","family":"Heberer","sequence":"first","affiliation":[{"name":"VA Palo Alto Healthcare System, Palo Alto, California"},{"name":"VA Palo Alto Cooperative Studies Program Coordinating Center, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam P.","family":"Bress","sequence":"additional","affiliation":[{"name":"VA Salt Lake City Healthcare System, Salt Lake City, Utah"},{"name":"Department of Population Health Sciences, School of Medicine, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Cogill","sequence":"additional","affiliation":[{"name":"VA Palo Alto Healthcare System, Palo Alto, California"},{"name":"VA Palo Alto Cooperative Studies Program Coordinating Center, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana I.","family":"Maldonado","sequence":"additional","affiliation":[{"name":"VA Palo Alto Healthcare System, Palo Alto, California"},{"name":"VA Palo Alto Cooperative Studies Program Coordinating Center, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun H.","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Gerontology, and Metabolism, Department of Medicine, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shriram","family":"Nallamshetty","sequence":"additional","affiliation":[{"name":"VA Palo Alto Healthcare System, Palo Alto, California"},{"name":"Division of Cardiovascular Medicine, Stanford School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying Q.","family":"Chen","sequence":"additional","affiliation":[{"name":"VA Palo Alto Healthcare System, Palo Alto, California"},{"name":"VA Palo Alto Cooperative Studies Program Coordinating Center, Palo Alto, California"},{"name":"Stanford Prevention Research Center, Department of Medicine, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Chiung","family":"Shih","sequence":"additional","affiliation":[{"name":"VA Palo Alto Healthcare System, Palo Alto, California"},{"name":"VA Palo Alto Cooperative Studies Program Coordinating Center, Palo Alto, California"},{"name":"Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Lynch","sequence":"additional","affiliation":[{"name":"VA Salt Lake City Healthcare System, Salt Lake City, Utah"},{"name":"Division of Epidemiology, School of Medicine, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Lee","sequence":"additional","affiliation":[{"name":"VA Palo Alto Healthcare System, Palo Alto, California"},{"name":"VA Palo Alto Cooperative Studies Program Coordinating Center, Palo Alto, California"},{"name":"Division of Endocrinology, Gerontology, and Metabolism, Department of Medicine, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"ebr250010r1","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70162","article-title":"Trends in the utilization, expenditure and costs of noninsulin glucose-lowering drugs in the Medicaid population: steady increases in glucagon-like peptide-1 receptor agonist and sodium-glucose transporter-2 inhibitor use, prices and expenditure.","author":"Almadfaa","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"ebr250010r2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.26327","article-title":"Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes.","volume":"8","author":"Wang","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"5","key":"ebr250010r3","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1001\/jamaophthalmol.2025.0349","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy risk among patients with diabetes.","volume":"143","author":"Hsu","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"ebr250010r4","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1111\/dom.16316","article-title":"Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: a Danish-Norwegian cohort study.","volume":"27","author":"Simonsen","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"ebr250010r5","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide.","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"ebr250010r6","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ophtha.2024.10.030","article-title":"Association between semaglutide and nonarteritic anterior ischemic optic neuropathy: a multinational population-based study.","volume":"132","author":"Chou","year":"2025","journal-title":"Ophthalmology"},{"key":"ebr250010r7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ajo.2025.02.025","article-title":"The effect of semaglutide and GLP-1 RAs on risk of nonarteritic anterior ischemic optic neuropathy.","volume":"274","author":"Abbass","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"ebr250010r8","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1001\/jamaophthalmol.2024.6555","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy.","volume":"143","author":"Cai","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"ebr250010r9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.26321","article-title":"GLP-1 receptor agonists and sight-threatening ophthalmic complications in patients with type 2 diabetes.","volume":"8","author":"Ramsey","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"7","key":"ebr250010r10","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glaf028","article-title":"Effect of initiation and continuous adherence to ARBs versus ACEIs on risk of adjudicated mild cognitive impairment or dementia.","volume":"80","author":"Derington","year":"2025","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"9","key":"ebr250010r13","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1001\/jamaophthalmol.2025.2489","article-title":"Ocular adverse events with semaglutide: a systematic review and meta-analysis.","volume":"143","author":"Natividade","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"ebr250010r14","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1001\/jamaophthalmol.2025.2493","article-title":"Semaglutide and the eyes-a literature glut, but little clarity.","volume":"143","author":"Li","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"ebr250010r15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1001\/jamaophthalmol.2024.6058","article-title":"Ophthalmic complications associated with the antidiabetic drugs semaglutide and tirzepatide.","volume":"143","author":"Katz","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"ebr250010r16","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/WNO.0000000000002163","article-title":"Validity of administrative coding for nonarteritic ischemic optic neuropathy.","volume":"44","author":"Hamedani","year":"2024","journal-title":"J Neuroophthalmol"},{"issue":"4","key":"ebr250010r17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1097\/WNO.0000000000000870","article-title":"Unraveling the enigma of nonarteritic anterior ischemic optic neuropathy.","volume":"39","author":"Rizzo","year":"2019","journal-title":"J Neuroophthalmol"},{"key":"ebr250010r11","unstructured":"Zhou? T, Tong? G, Li? F, Thomas? LE, Li? F. PSweight: an R package for propensity score weighting analysis. Accessed January 8, 2026. https:\/\/journal.r-project.org\/articles\/RJ-2022-011"},{"key":"ebr250010r12","unstructured":"Van Buuren? S, Groothuis-Oudshoorn? K. Mice: multivariate imputation by chained equations in R. Accessed January 8, 2026. https:\/\/www.jstatsoft.org\/article\/view\/v045i03"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2844873\/jamaophthalmology_heberer_2026_br_250010_1775573903.7308.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:00:28Z","timestamp":1775746828000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2844873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2025.6262","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}